Syntone Ventures Llc - Net Worth and Insider Trading

Syntone Ventures Llc Net Worth

The estimated net worth of Syntone Ventures Llc is at least $8 Million dollars as of 2024-04-27. Syntone Ventures Llc is the 10% Owner of Outlook Therapeutics Inc and owns about 991,152 shares of Outlook Therapeutics Inc (OTLK) stock worth over $8 Million. Details can be seen in Syntone Ventures Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Syntone Ventures Llc has not made any transactions after 2021-02-03 and currently still holds the listed stock(s).

Transaction Summary of Syntone Ventures Llc

To

Syntone Ventures Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Syntone Ventures Llc owns 1 companies in total, including Outlook Therapeutics Inc (OTLK) .

Click here to see the complete history of Syntone Ventures Llc’s form 4 insider trades.

Insider Ownership Summary of Syntone Ventures Llc

Ticker Comapny Transaction Date Type of Owner
OTLK Outlook Therapeutics Inc 2021-02-03 10 percent owner

Syntone Ventures Llc Latest Holdings Summary

Syntone Ventures Llc currently owns a total of 1 stock. Syntone Ventures Llc owns 991,152 shares of Outlook Therapeutics Inc (OTLK) as of February 3, 2021, with a value of $8 Million.

Latest Holdings of Syntone Ventures Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OTLK Outlook Therapeutics Inc 2021-02-03 991,152 8.43 8,355,411

Holding Weightings of Syntone Ventures Llc


Syntone Ventures Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Syntone Ventures Llc has made a total of 2 transactions in Outlook Therapeutics Inc (OTLK) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Outlook Therapeutics Inc is the acquisition of 150,000 shares on February 3, 2021, which cost Syntone Ventures Llc around $3 Million.

Insider Trading History of Syntone Ventures Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Syntone Ventures Llc Trading Performance

GuruFocus tracks the stock performance after each of Syntone Ventures Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Syntone Ventures Llc is 11.79%. GuruFocus also compares Syntone Ventures Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Syntone Ventures Llc within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Syntone Ventures Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Syntone Ventures Llc

Average Return

27.49%

Average return per transaction

Outperforming Transactions

50%

1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 19.09 11.79 26.18 27.49 -9.74 -15.54
Relative Return to S&P 500(%) 16.96 3.08 10.05 1.47 -16.41 -25.93

Syntone Ventures Llc Ownership Network

Ownership Network List of Syntone Ventures Llc

No Data

Ownership Network Relation of Syntone Ventures Llc


Syntone Ventures Llc Owned Company Details

What does Outlook Therapeutics Inc do?

Who are the key executives at Outlook Therapeutics Inc?

Syntone Ventures Llc is the 10 percent owner of Outlook Therapeutics Inc. Other key executives at Outlook Therapeutics Inc include Chief Commercial Officer Jeff Evanson , Chief Operating Officer Terry Dagnon , and director & CEO and President Trenary C Russell Iii .

Outlook Therapeutics Inc (OTLK) Insider Trades Summary

Over the past 18 months, Syntone Ventures Llc made no insider transaction in Outlook Therapeutics Inc (OTLK). Other recent insider transactions involving Outlook Therapeutics Inc (OTLK) include a net sale of 368,671 shares made by Jeff Evanson , a net sale of 520,000 shares made by Terry Dagnon , and a net purchase of 1,882 shares made by Yezan Munther Haddadin .

In summary, during the past 3 months, insiders sold 0 shares of Outlook Therapeutics Inc (OTLK) in total and bought 5,006 shares, with a net purchase of 5,006 shares. During the past 18 months, 47,558 shares of Outlook Therapeutics Inc (OTLK) were sold and 5,006 shares were bought by its insiders, resulting in a net sale of 42,552 shares.

Outlook Therapeutics Inc (OTLK)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Outlook Therapeutics Inc Insider Transactions

No Available Data

Syntone Ventures Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Syntone Ventures Llc. You might contact Syntone Ventures Llc via mailing address: 1517 Champlain Crest Way, Cary Nc 27513.

Discussions on Syntone Ventures Llc

No discussions yet.